Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: Might it be the reason for their 'innocent' profile?

Annals of the Rheumatic Diseases

Volumn 70, Issue 2, 2011, Pages 380-383

  Andreoli, Laura ^a   Nalli, Cecilia ^a   Motta, Mario ^b   Norman, Gary L ^c   Shums, Zakera ^c   Encabo, Susan ^c   Binder, Walter L ^c   Nuzzo, Monica ^a   Frassi, Micol ^a   Lojacono, Andrea ^d   Avcin, Tadej ^e   Meroni, Pier Luigi ^f   Tincani, Angela ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NICU   (Italy)

^c INOVA DIAGNOSTICS INC   (United States)

^d Obstetrics and Gynecology   (Italy)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G;

ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; INFANT; MAJOR CLINICAL STUDY; MOTHER; PRESCHOOL CHILD; PRIORITY JOURNAL; SYSTEMIC DISEASE; BIOSYNTHESIS; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE;

ADULT; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 78751704220     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.137281     Document Type: Article

References (17)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34:236-50.
3. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010;9:A299-304.
4. Iverson GM, von Mühlen CA, Staub HL, et al. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006;27:266-71.
5. Arvieux J, Renaudineau Y, Mane I, et al. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 2002;87:599-605. (Pubitemid 34302947)
6. Ambrozic A, Avicin T, Ichikawa K, et al. Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol 2002;14:823-30.
7. Avcin T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford) 2001;40:565-73. (Pubitemid 32514725)
8. Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol 2006;23:247-51.
9. Tincani A, Filippini M, Scarsi M, et al. European attempts for the standardisation of the antiphospholipid antibodies. Lupus 2009;18:913-9.
10. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I-function in health and disease. Thromb Res 2004;114:335-46. (Pubitemid 39422565)
11. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998;95:15542-6.
12. de Laat B, Derksen RH, Urbanus RT, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-5.
13. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42.
14. Balestrieri G, Tincani A, Spatola L, et al. Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:122-30.
15. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767-73.
16. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003;23:377-83.
17. Shoenfeld Y, Meroni PL, Cervera R. Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 2008;67:438-42. (Pubitemid 351498420)